Navigation

Pulmonary arterial hypertension (adults) - drugs [ID12]

Drugs for the treatment of pulmonary arterial hypertension

Status: Discontinued
Expected date of issue: TBC
Referral date: April 2005
Process: MTA
Topic area:
  • Cardiovascular
  • Therapeutic procedures
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Helen Knight
Communications manager: Kristin O'Leary
Project manager: Jeremy Powell
Assessment Group / Evidence Review Group: West Midlands Health Technology Assessment Collaboration
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: October 2006
Closing date for invited submissions / evidence submission: 10 May 2007
Final scope published: January 2007
1st appraisal committee meeting: 03 October 2007
2nd appraisal committee meeting: 05 February 2008
3rd appraisal committee meeting: 03 April 2008
Top


 

Consultees and commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Actelion Pharmaceuticals UK Ltd (bosentan)
  • Encysive pharmaceuticals UK Ltd (sitaxsentan)
  • GlaxoSmithKline (epoprostenol)
  • Pfizer Ltd (Sildenafil citrate)
  • Bayer Schering Pharma (iloprost)

Patient / Carer Groups

  • Pulmonary Hypertension Association UK
  • Raynaud's and Scleroderma Association
  • Scleroderma Society

Professional Groups

  • British Cardiovascular Society
  • British Heart Foundation
  • British Society for Rheumatology
  • British Thoracic Society
  • National Pulmonary Hypertension Service
  • Royal College of Nursing
  • Royal College of Physicians

Others

  • Department of Health
  • London specialised commissioning Group
  • West Midlands Specialised Commissioning Team
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • NHS Quality Improvement Scotland

Comparator Manufacturers

  • None

Assessment Team

  • National Coordinating Centre for Health Technology Assessment
  • West Midlands Health Technology Assessment Collaboration

Research Groups

  • British Society for Cardiovascular Research

Top


 

Project history

Date Update
27 May 2005 Topic summary published.
17 October 2007 Timelines extended to accommodate additional analysis requested by the committee. Second committee meeting rescheduled.
09 November 2007 Request to stakeholders seeking additional observational or registry data on the survival benefit provided by the drugs that are subject to this appraisal.
28 October 2008 Consultees and commentators were invited to comment on a revised remit, scope and provisional matrix
25 November 2008
Closing date for comment on draft scope, remit and matrix
30 March 2009
The appraisal was removed from the NICE work programme
Top


 

Key documents

This page was last updated: 05 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.